{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:27:51Z","timestamp":1794889671466,"version":"4.9.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-995882"],"award-info":[{"award-number":["R-995882"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2023\u20131055"],"award-info":[{"award-number":["FAI-2023\u20131055"]}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-1000881"],"award-info":[{"award-number":["OLL-1000881"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nanna Svartz Foundation","award":["2021\u201300436"],"award-info":[{"award-number":["2021\u201300436"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024\u201343"],"award-info":[{"award-number":["2024\u201343"]}]},{"name":"Region Stockholm","award":["FoUI-1004114"],"award-info":[{"award-number":["FoUI-1004114"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the efficacy of belimumab on mucocutaneous manifestations of SLE in a large integrative analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using data from five phase III clinical trials (BLISS-52; BLISS-76; BLISS-NEA; EMBRACE; BLISS-SC; N\u2009=\u20093086), we investigated the effect of belimumab vs. placebo on top of standard therapy on inducing improvement in mucocutaneous BILAG (mcBILAG) and mucocutaneous SLE Disease Activity Index 2000 (mcSLEDAI-2K), and on preventing mcBILAG flares. We employed logistic and Cox regression analysis, adjusting for trial variance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Belimumab was superior to placebo in inducing mcBILAG (week-52 OR: 1.29; 95% CI: 1.07\u20131.57; P = 0.008) and mcSLEDAI-2K (week-52 OR: 1.37; 95% CI: 1.16\u20131.62; P&amp;lt; 0.001) improvement, as well as in inducing sustained (\u22652 visits, maintained through week 52) mcBILAG (HR: 1.23; 95% CI: 1.07\u20131.41; P = 0.003) and mcSLEDAI-2K (HR: 1.24; 95% CI: 1.17\u20131.31; P &amp;lt; 0.001) improvement. These associations held true for patients with SLEDAI-2K \u226510 and positive anti-dsDNA levels at baseline, but not their counter groups. Belimumab prevented mcBILAG flares to a greater extent than placebo in patients with positive anti-dsDNA levels (HR: 0.70; 95% CI: 0.50\u20130.98; P = 0.035) and with a near-significant separation in patients with baseline SLEDAI-2K \u226510 (HR: 0.71; 95% CI: 0.51\u20131.00; P = 0.050), whereas no difference was seen in their counter groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Belimumab is superior to placebo in inducing improvement and in preventing flares in the mucocutaneous domain of SLE, especially in patients with high disease activity and in serologically active patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf145","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T14:20:26Z","timestamp":1741962026000},"page":"4257-4266","source":"Crossref","is-referenced-by-count":12,"title":["Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large <i>post hoc<\/i> analysis of five phase III clinical trials"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0624-7009","authenticated-orcid":false,"given":"Giorgia","family":"Grosso","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4274-8793","authenticated-orcid":false,"given":"Nefeli","family":"Giannopoulou","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4815-7477","authenticated-orcid":false,"given":"Alexander","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-841X","authenticated-orcid":false,"given":"Nursen","family":"Cetrez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9894-6966","authenticated-orcid":false,"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-9471","authenticated-orcid":false,"given":"Julius","family":"Lindblom","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM) , Stockholm,","place":["Sweden"]},{"name":"Faculty of Medicine and Health, Department of Rheumatology, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025070205023447900_keaf145-B1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"2025070205023447900_keaf145-B2","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.3390\/jcm11226869","article-title":"Clinical heterogeneity, unmet needs and long-term outcomes in patients with systemic lupus erythematosus","volume":"11","author":"Sj\u00f6wall","year":"2022","journal-title":"J Clin Med"},{"key":"2025070205023447900_keaf145-B3","doi-asserted-by":"crossref","first-page":"952304","DOI":"10.3389\/fmed.2022.952304","article-title":"B cells in systemic lupus erythematosus: targets of new therapies and surveillance tools","volume":"9","author":"Parodis","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025070205023447900_keaf145-B4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous involvement in systemic lupus erythematosus: a review for the rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J Rheumatol"},{"key":"2025070205023447900_keaf145-B5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"2025070205023447900_keaf145-B6","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2025070205023447900_keaf145-B7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2025070205023447900_keaf145-B8","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025070205023447900_keaf145-B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025070205023447900_keaf145-B10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025070205023447900_keaf145-B11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025070205023447900_keaf145-B12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025070205023447900_keaf145-B13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025070205023447900_keaf145-B14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","article-title":"Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review","volume":"9","author":"Huang","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025070205023447900_keaf145-B15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/mr\/road078","article-title":"Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: a retrospective study","volume":"34","author":"Hasegawa","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025070205023447900_keaf145-B16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025070205023447900_keaf145-B17","doi-asserted-by":"crossref","first-page":"2207671","DOI":"10.1080\/0886022X.2023.2207671","article-title":"Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren Fail"},{"key":"2025070205023447900_keaf145-B18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025070205023447900_keaf145-B19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2025070205023447900_keaf145-B20","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025070205023447900_keaf145-B21","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"key":"2025070205023447900_keaf145-B22","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025070205023447900_keaf145-B23","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025070205023447900_keaf145-B24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025070205023447900_keaf145-B25","doi-asserted-by":"crossref","first-page":"e000118","DOI":"10.1136\/lupus-2015-000118","article-title":"Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA","volume":"3","author":"Collins","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2025070205023447900_keaf145-B26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40744-016-0047-x","article-title":"First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany study","volume":"3","author":"Schwarting","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2025070205023447900_keaf145-B27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/jpm13040691","article-title":"Early and late response and glucocorticoid-sparing effect of belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the belimumab in real life setting study-joint and skin (BeRLiSS-JS)","volume":"13","author":"Zen","year":"2023","journal-title":"J Pers Med"},{"key":"2025070205023447900_keaf145-B28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14712598.2018.1494719","article-title":"Smoking reduces the efficacy of belimumab in mucocutaneous lupus","volume":"18","author":"Parodis","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025070205023447900_keaf145-B29","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3899\/jrheum.150470","article-title":"Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices","volume":"42","author":"Hui-Yuen","year":"2015","journal-title":"J Rheumatol"},{"key":"2025070205023447900_keaf145-B30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10067-020-05315-w","article-title":"Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016-2019)","volume":"40","author":"Scheinberg","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025070205023447900_keaf145-B31","doi-asserted-by":"crossref","first-page":"A534","DOI":"10.1016\/j.jval.2014.08.1703","article-title":"Evaluation of use of belimumab in clinical practice settings (observe study) in spain: health resource utilization and labour absenteeism","volume":"17","author":"Cortes","year":"2014","journal-title":"Value Health"},{"key":"2025070205023447900_keaf145-B32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2025070205023447900_keaf145-B33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/0961203320947814","article-title":"Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: results from a 24-month OBSErve study in Argentina","volume":"29","author":"Babini","year":"2020","journal-title":"Lupus"},{"key":"2025070205023447900_keaf145-B34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00296-017-3682-9","article-title":"Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study","volume":"37","author":"Touma","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025070205023447900_keaf145-B35","first-page":"w20022","article-title":"Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland","volume":"149","author":"von Kempis","year":"2019","journal-title":"Swiss Med Wkly"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf145\/62415118\/keaf145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4257\/62415118\/keaf145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4257\/62415118\/keaf145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:02:43Z","timestamp":1751446963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/7\/4257\/8078618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,14]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf145","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,14]]}}}